Sanofi wagers $400m on miRecule muscular dystrophy therapy
pharmaphorum
OCTOBER 5, 2022
There’s little detail on the focus of the alliance, although TrialSpark’s main focus is on rheumatology, dermatology, central nervous system, and cardiometabolic diseases. The aim will be to identify promising candidates in areas of “unmet patient need.”
104 
Let's personalize your content